- PF708-301 findings show comparable overall profiles of PF708 and Forteo®
- No imbalances in severity or incidence of adverse events
- Company is on track for submission of NDA in third quarter 2018
- Management will hold a conference call and webcast today at 4:45 p.m. ET/1:45 p.m. PT to discuss the results
PR Newswire
SAN DIEGO, May 14, 2018